Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05048563 · ClinicalTrials.gov registry record
Registry of Thiola EC Therapy
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 25
- Enrollment target
NCT05048563 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 25 participants.
The verdict
NCT05048563 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
Thiola EC represents several modifications of Thiola that promise better, more efficacious therapy of cystinuria. First, pill size has changed from 100 mg to 300 mg, meaning that typical pill burden will be reduced from, on average, 10 pills per day to 3-5 pills per day. This change will be welcomed by patients whose fluid intake and administration of potassium citrate are daily impositions. Second, the preparation is now enteric-coated, formulated to offer delayed release of active tiopronin. Lastly, Thiola EC can be taken with food which is an improvement to the inconvenient dosing regimen of Thiola, which can only be taken one hour before, or two hours after meals. These changes may affect compliance and side effect profiles compared to those of Thiola. In combination with potassium citrate or other alkali preparations, adverse GI effects are relatively common in actively-treated patients with cystinuria. It is possible that GI side effects may be reduced by Thiola EC.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-03-02 |
| Est. Completion | 2023-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05048563
The ClinicalTrials.gov registry entry for NCT05048563 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05048563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05048563 about?
NCT05048563 is a clinical study titled "Registry of Thiola EC Therapy". Thiola EC represents several modifications of Thiola that promise better, more efficacious therapy of cystinuria. First, pill size has changed from 100 mg to 300 mg, meaning that typical pill burden will be reduced from, on average, 10 pills per day to 3-5 pills per day. This change will be welcomed...
What is the current status of trial NCT05048563?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2021-03-02. Estimated completion is 2023-10-31.
Who is sponsoring clinical trial NCT05048563?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.